CÃ¡rmen BrÃ¡s-Silva

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7912187/publications.pdf

Version: 2024-02-01

48	1,019	471509	501196
papers	citations	17 h-index	28 g-index

53	53	53	1593
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension. Current Problems in Cardiology, 2022, 47, 100860.	2.4	3
2	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	5
3	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension. Biomolecules, 2022, 12, 484.	4.0	11
4	Urocortins as biomarkers in cardiovascular disease. Clinical Science, 2022, 136, 1-14.	4.3	1
5	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovascular Research, 2021, 117, 2474-2488.	3.8	20
6	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. Frontiers in Pediatrics, 2020, 8, 342.	1.9	35
7	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. European Journal of Pharmacology, 2020, 889, 173658.	3.5	7
8	Novel insights into the role of urotensin II in cardiovascular disease. Drug Discovery Today, 2019, 24, 2170-2180.	6.4	18
9	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. Cardiovascular Drugs and Therapy, 2019, 33, 599-613.	2.6	7
10	Neuregulinâ€1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 255-265.	1.9	11
11	Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 2019, 139, 932-948.	1.6	74
12	Update on pathophysiology and preventive strategies of anthracyclineâ€induced cardiotoxicity. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 204-215.	1.9	39
13	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893.	3.8	52
14	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. Cardiovascular Research, 2018, 114, 1165-1177.	3.8	19
15	Effects of urocortin-2 on cellular Ca2+ homeostasis in right heart failure induced by pulmonary artery hypertension. , 2018, , .		1
16	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
17	Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. , 2018, , .		0
18	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. Experimental Physiology, 2017, 102, 411-421.	2.0	5

#	Article	IF	Citations
19	Distinct right ventricle remodeling in response to pressure overload in the rat. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H85-H95.	3.2	33
20	Pulmonary arterial hypertension: Basic knowledge for clinicians. Archives of Cardiovascular Diseases, 2016, 109, 550-561.	1.6	34
21	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. Cardiovascular Research, 2016, 109, 44-54.	3.8	33
22	Cardiotoxicity of Cancer Chemotherapyâ€“Recent Developments. , 2016, , 36-83.		1
23	Urocortin 2 in cardiovascular health and disease. Drug Discovery Today, 2015, 20, 906-914.	6.4	25
24	P505Neuregulin-1 ameliorates right ventricular diastolic dysfunction in pulmonary arterial hypertension. Cardiovascular Research, 2014, 103, S92.4-S92.	3.8	0
25	P755Molecular mechanisms underlying the beneficial effects of neuregulin-1 in pulmonary arterial hypertension. Cardiovascular Research, 2014, 103, S138.3-S138.	3.8	0
26	Angiotensin-(1â€“7) Modulates Angiotensin II-Induced Vasoconstriction in Human Mammary Artery. Cardiovascular Drugs and Therapy, 2014, 28, 513-522.	2.6	18
27	Therapeutic potential of neuregulin-1 in cardiovascular disease. Drug Discovery Today, 2013, 18, 836-842.	6.4	49
28	Intraventricular pressure gradients throughout the cardiac cycle: effects of ischaemia and modulation by afterload. Experimental Physiology, 2013, 98, 149-160.	2.0	16
29	Cardiotoxicidade associada Ã terapÃªutica oncolÃ³gica: mecanismos fisiopatolÃ³gicos e estratÃ©gias de prevenÃ§Ã£o. Revista Portuguesa De Cardiologia, 2013, 32, 395-409.	0.5	62
30	Rodent models of heart failure: an updated review. Heart Failure Reviews, 2013, 18, 219-249.	3.9	62
31	Neuregulin-1 modulates right ventricle cardiomyocyte function in pulmonary arterial hypertension. European Heart Journal, 2013, 34, P5029-P5029.	2.2	0
32	Left intraventricular diastolic and systolic pressure gradients. Experimental Biology and Medicine, 2011, 236, 1364-1372.	2.4	10
33	A Western-Type Diet Attenuates Pulmonary Hypertension with Heart Failure and Cardiac Cachexia in Rats. Journal of Nutrition, 2011, 141, 1954-1960.	2.9	17
34	Effects of adrenomedullin on systolic and diastolic myocardial function. Peptides, 2009, 30, 796-802.	2.4	8
35	Abstract 5956: Modulation of Urocortin 2 Contractile EFFects by Endocardial Endothelium. Circulation, 2008, 118, .	1.6	0
36	Myocardial effects of endothelin-1. Revista Portuguesa De Cardiologia, 2008, 27, 925-51.	0.5	9

#	Article	IF	Citations
37	Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 376, 107-115.	3.0	13
38	149 The acute decrease of myocardial stiffness induced by beta-adrenergic stimulation is independent of the endocardial endothelium and prostaglandins release. European Journal of Heart Failure, Supplement, 2007, 6, 38-38.	0.0	0
39	154 Urocortin 2 acutely decreases myocardial stiffness. European Journal of Heart Failure, Supplement, 2007, 6, 39-40.	0.0	0
40	55 Time dependent increase in myocardial distensibility after an acute preload elevation. European Journal of Heart Failure, Supplement, 2007, 6, 9-9.	0.0	0
41	Myocardial dysfunction and neurohumoral activation without remodeling in left ventricle of monocrotaline-induced pulmonary hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1587-H1594.	3.2	57
42	Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis. , 2006, 111, 508-531.		155
43	M-mode and Doppler echocardiographic reference values for male New Zealand white rabbits. American Journal of Veterinary Research, 2006, 67, 1725-1729.	0.6	30
44	Obligatory role of the endocardial endothelium in the increase of myocardial distensibility induced by endothelin-1. Experimental Biology and Medicine, 2006, 231, 876-81.	2.4	3
45	Impaired response to ET(B) receptor stimulation in heart failure: functional evidence of endocardial endothelial dysfunction?. Experimental Biology and Medicine, 2006, 231, 893-8.	2.4	6
46	Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1194-H1199.	3.2	22
47	ET-1 increases distensibility of acutely loaded myocardium: a novel ET_Aand Na⁺/H⁺exchanger-mediated effect. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1332-H1339.	3.2	26
48	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	8